Petros Pharmaceuticals (PTPI)
Builds SaaS and SaMD tools for prescription-to-OTC drug switches.
Something off on this page? Send us feedback.
Petros Pharmaceuticals is a healthcare technology company developing SaaS and potential SaMD tools to help drug sponsors pursue prescription-to-OTC switches. It has exited its former Stendra and vacuum-device businesses, making execution dependent on platform development, regulatory acceptance and financing.
Petros Pharmaceuticals has shifted from a men’s health products company into a small healthcare technology developer focused on prescription-to-OTC transitions. Its historical operations included Stendra, an FDA-approved erectile dysfunction medicine licensed from Vivus, and vacuum erection device brands sold through former subsidiaries. The company discontinued Stendra wholesaler sales, ended the Vivus license, and assigned the former device businesses for the benefit of creditors.
Its current plan centers on a proprietary platform with SaaS and potential Software as a Medical Device components. The tools are intended to help pharmaceutical sponsors manage regulatory, labeling, self-selection and market-access steps for nonprescription products with an Additional Condition for Nonprescription Use. The business remains early stage, with no platform revenue disclosed, and depends on successful software development, FDA pathway alignment, customer adoption and continued access to capital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $0 · Total assets $3.5M · Shareholders' equity $700.9K
- Revenue
- $0
- Operating income
- −$988.5K
- Net income
- −$955.6K
No dividends on record.
| Insiders6 holders · as of Jun 25, 2026 | 35.33% | 14.97M shares | |
| Strategic holders1 holder · as of Feb 17, 2026 | 10.38% | 4.40M shares | |
| Otherremainder | 54.29% | 23.00M shares |
42.37M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Joshua SilvermanInsiderdirector | 20.75% | 8.79M | Form 4filed Jun 5, 2026 ↗ |
Iroquois Capital Management, LLCStrategic | 10.38% | 4.40M | 13Gfiled Feb 17, 2026 ↗ |
Bruce BernsteinInsiderdirector | 8.88% | 3.76M | Form 4filed Jun 5, 2026 ↗ |
Fady BoctorInsiderofficer: See Remarks | 2.11% | 894,986 | Form 4filed Jun 5, 2026 ↗ |
Wayne Remell WalkerInsiderdirector | 2.08% | 881,333 | Form 4filed Jun 8, 2026 ↗ |
| See all 14 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
Not reported.